Nanoparticle-based brachytherapy spacers for delivery of localized combined chemoradiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 2, 2015, Pages 393-400

  Kumar, Rajiv ^a,b   Belz, Jodi ^a   Markovic, Stacey ^c   Jadhav, Tej ^a   Fowle, William ^a   Niedre, Mark ^c   Cormack, Robert ^b   Makrigiorgos, Mike G ^b   Sridhar, Srinivas ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b Northeastern University   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADATION; CHEMORADIOTHERAPY; CONTROLLED DRUG DELIVERY; DISINTEGRATION; DRUG PRODUCTS; INFRARED DEVICES; MAMMALS; NANOPARTICLES; ONCOLOGY; RADIOTHERAPY; SILICA; SILICA NANOPARTICLES; TARGETED DRUG DELIVERY; TISSUE;

CHEMORADIATION THERAPIES; INSTRUMENTATION TECHNIQUES; METHODS AND MATERIALS; NEAR-INFRARED FLUOROPHORES; OPTICAL FLUORESCENCE; POLY LACTIC-CO-GLYCOLIC ACID; THERAPEUTIC BENEFITS; THERAPEUTIC EFFICACY;

SHIMS;

DOCETAXEL; GOLD NANOPARTICLE; POLY(LACTIC CO GLYCOLIC) ACID; POLYMER; SILICA NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG IMPLANT; NANOCAPSULE; SILICON DIOXIDE; TAXOID;

ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; BIODEGRADATION; BRACHYTHERAPY; BRACHYTHERAPY IMPLANT; BRACHYTHERAPY SPACER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHEMORADIOTHERAPY; DYNAMIC LIGHT SCATTERING; ELECTRON MICROSCOPY; ENERGY DISPERSIVE SPECTROSCOPY; FLUORESCENCE; FLUORESCENCE IMAGING; GLASS TRANSITION TEMPERATURE; LIGHT SCATTERING; MOLECULAR WEIGHT; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; OPTICAL FLUORESCENCE; PRIORITY JOURNAL; RADIOSENSITIZATION; SCANNING ELECTRON MICROSCOPY; SPECTROSCOPY; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT RESPONSE; WEIGHT REDUCTION; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; DEVICES; DRUG IMPLANT; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CELL LINE, TUMOR; CHEMORADIOTHERAPY; DRUG IMPLANTS; MICE; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; SILICON DIOXIDE; TAXOIDS; TREATMENT OUTCOME;

EID: 84922445828     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.10.041     Document Type: Article

References (43)

1. American Cancer Society, Cancer Facts and Figures 2014, (http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf).
2. Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol 2008;10:111-119.
3. Nath R, Anderson LL, Meli JA, et al. Code of practice for brachytherapy physics: Report of the AAPM radiation therapy committee task group no. 56. American Association of Physicists in Medicine. Med Phys 1997;24:1557-1598.
4. Dicker AP, Merrick G, Gomella L, et al. Basic and Advanced Techniques in Prostate Brachytherapy. New York, NY: Taylor & Francis, CRC Press; 2005.
5. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 1999;281:1598-1604.
6. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010;28:1106-1111.
7. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74.
8. Nguyen PL, Chen MH, D'Amico AV, et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: A prospective phase 2 study. Cancer 2007;110:1485-1492.
9. Nguyen PL, D'Amico AV, Lee AK, et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: A systematic review of the literature. Cancer 2007;110:1417-1428.
10. Lee WR. Permanent prostate brachytherapy: The significance of postimplant dosimetry. Rev Urol 2004;6(Suppl 4):S49-S56.
11. Cormack RA, Sridhar S, Suh WW, et al. Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices. Int J Radiat Oncol 2010;76:615-623.
12. Friedland JL, Freeman DE, Masterson-McGary ME, et al. Stereotactic body radiotherapy: An emerging treatment approach for localized prostate cancer. Technol Cancer Res T 2009;8:387-392.
13. Sylvester JE, Grimm PD, Eulau SM, et al. Permanent prostate brachytherapy preplanned technique: The modern Seattle method step-by-step and dosimetric outcomes. Brachytherapy 2009;8:197-206.
14. Tishler RB, Geard CR, Hall EJ, et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Research 1992;52:3495-3497.
15. Castro Kreder N, Van Bree C, Franken NA, et al. Effects of gemcitabine on cell survival and chromosome aberrations after pulsed low dose-rate irradiation. Journal of Radiation Research 2004;45:111-118.
16. Jong WH, Borm PJ. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine 2008;3:133-149.
17. Nyk M, Kumar R, Ohulchanskyy TY, et al. High contrast in vitro and in vivo photoluminescence bioimaging using near infrared to near infrared up-conversion in Tm3+ and Yb3+ doped fluoride nanophosphors. Nano Lett. 2008;8:3834-3838.
18. Parveen S, Misra R, Sahoo SK. Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012;8:147-166.
19. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002;54:631-651.
20. Kumar R, Roy I, Hulchanskyy TY, et al. Covalently dye-linked, surface-controlled, and bioconjugated organically modified silica nanoparticles as targeted probes for optical imaging. Acs Nano 2008;2:449-456.
21. Kumar R, Roy I, Ohulchanskky TY, et al. In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. Acs Nano 2010;4:699-708.
22. Nagesha DK, Tada DB, Stambaugh CK, et al. Radiosensitizer-eluting nanocoatings on gold fiducials for biological in-situ image-guided radio therapy (bis-igrt). Physics in medicine and biology 2010;55:6039-6052.
23. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 2011;3:1377-1397.
24. Lu JM, Wang XW, Marin-Muller C, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009;9:325-341.
25. Ohulchanskyy TY, Roy I, Goswami LN, et al. Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer. Nano Lett 2007;7:2835-2842.
26. Burns A, Ow H, Wiesner U. Fluorescent core-shell silica nanoparticles: Towards 'Lab on a particle' architectures for nanobiotechnology. Chem Soc Rev 2006;35:1028-1042.
27. Sahoo Y, Goodarzi A, Swihart MT, et al. Aqueous ferrofluid of magnetite nanoparticles: Fluorescence labeling and magnetophoretic control. J Phys Chem B 2005;109:3879-3885.
28. De Palma R, Peeters S, Van Bael MJ, et al. Silane ligand exchange to make hydrophobic superparamagnetic nanoparticles water-dispersible. Chem Mater 2007;19:1821-1831.
29. Slowing II, Trewyn BG, Giri S, et al. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv Funct Mater 2007;17:1225-1236.
30. Ghosh SK, Kim P, Zhang X, et al. A novel imaging approach for early detection of prostate cancer based on endogenous zinc sensing. Cancer Res 2010;70:6119-6127.
31. Boutet J, Herve L, Debourdeau M, et al. Bimodal ultrasound and fluorescence approach for prostate cancer diagnosis. J Biomed Opt 2009;14:064001-064007.
32. Sanfilippo N, Hardee ME, Wallach J. Review of chemoradiotherapy for high-risk prostate cancer. Rev Recent Clin Trials 2011;6:64-68.
33. Bolla M, Hannoun-Levi JM, Ferrero JM, et al. Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: Preliminary results of a multicentre phase II trial. Radiother Oncol 2010;97:312-317.
34. Study NCT00116142. Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer, http://www.clinicaltrials.gov/ct2/show/study/NCT00116142.
35. Patel KJ, Tredan O, Tannock IF. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother Pharmacol 2013;72:127-138.
36. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997;49:403-449.
37. Mittal G, Sahana DK, Bhardwaj V, et al. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release 2007;119:77-85.
38. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-234.
39. Italia JL, Bhatt DK, Bhardwaj V, et al. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison tosandimmune neoral. JControl Release 2007;119:197-206.
40. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991;88:11460-11464.
41. Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 2005;5:161-171.
42. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-760.
43. Ngwa W, Korideck H, Kassis AI, et al. In vitro radiosensitization by gold nanoparticles during continuous low-dose-rate gamma irradiation with i-125 brachytherapy seeds. Nanomedicine-Uk 2013;9:25-27.